Evidence map›Paper›PMID 24235145›Full record

ArticleThe Journal of biological chemistry2014

Automethylation activities within the mixed lineage leukemia-1 (MLL1) core complex reveal evidence supporting a "two-active site" model for multiple histone H3 lysine 4 methylation.

Anamika Patel, Valarie E Vought, Stephen Swatkoski, Susan Viggiano, Benny Howard, Venkatasubramanian Dharmarajan, Kelsey E Monteith, Gillian Kupakuwana, Kevin E Namitz, Stephen A Shinsky and 2 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Multistate structures of the MLL1-WRAD complex bound to H2B-ubiquitinated nucleosome.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Anamika PatelFrom the Department of Biochemistry and Molecular Biology, State University of New York Upstate Medical University, Syracuse, New York 13210.
Valarie E Vought
Stephen Swatkoski
Susan Viggiano
Benny Howard
Venkatasubramanian Dharmarajan
Kelsey E Monteith
Gillian Kupakuwana
Kevin E Namitz
Stephen A Shinsky
Robert J Cotter
Michael S Cosgrove
SUNY Upstate Medical University · USSyracuse University · USJohns Hopkins Medicine · USJohns Hopkins University · US

Funding

Molecular Mechanisms for the Assembly and Regulation of the MLL1 Core ComplexR01CA140522 · NCI · UPSTATE MEDICAL UNIVERSITY · PI COSGROVE, MICHAEL S. · 2010 to 2019
$3.6M
NCI NIH HHS R01 CA140522NCI NIH HHS R01CA140522
6 · The paper itself

Abstract

The mixed lineage leukemia-1 (MLL1) core complex predominantly catalyzes mono- and dimethylation of histone H3 at lysine 4 (H3K4) and is frequently altered in aggressive acute leukemias. The molecular mechanisms that account for conversion of mono- to dimethyl H3K4 (H3K4me1,2) are not well understood. In this investigation, we report that the suppressor of variegation, enhancer of zeste, trithorax (SET) domains from human MLL1 and Drosophila Trithorax undergo robust intramolecular automethylation reactions at an evolutionarily conserved cysteine residue in the active site, which is inhibited by unmodified histone H3. The location of the automethylation in the SET-I subdomain indicates that the MLL1 SET domain possesses significantly more conformational plasticity in solution than suggested by its crystal structure. We also report that MLL1 methylates Ash2L in the absence of histone H3, but only when assembled within a complex with WDR5 and RbBP5, suggesting a restraint for the architectural arrangement of subunits within the complex. Using MLL1 and Ash2L automethylation reactions as probes for histone binding, we observed that both automethylation reactions are significantly inhibited by stoichiometric amounts of unmethylated histone H3, but not by histones previously mono-, di-, or trimethylated at H3K4. These results suggest that the H3K4me1 intermediate does not significantly bind to the MLL1 SET domain during the dimethylation reaction. Consistent with this hypothesis, we demonstrate that the MLL1 core complex assembled with a catalytically inactive SET domain variant preferentially catalyzes H3K4 dimethylation using the H3K4me1 substrate. Taken together, these results are consistent with a "two-active site" model for multiple H3K4 methylation by the MLL1 core complex.

Indexed as

Amino Acid SubstitutionAnimalsBinding SitesCysteineDNA-Binding ProteinsElectrophoresis, Polyacrylamide GelHistone-Lysine N-MethyltransferaseHistonesHumansIntracellular Signaling Peptides and ProteinsKineticsLysineMass SpectrometryMethylationModels, MolecularMutationASH2L protein, humanCysteineDNA-Binding ProteinsHistone-Lysine N-MethyltransferaseHistonesIntracellular Signaling Peptides and ProteinsKMT2A protein, humanLysineMyeloid-Lymphoid Leukemia ProteinNuclear ProteinsRBBP5 protein, humanTranscription FactorsWDR5 protein, humanAutomethylationChromatin Histone ModificationEnzyme MechanismsEpigeneticsHistone MethylationLeukemiaSelf-methylation

Identifiers

PMID24235145
PMCPMC3887211
OpenAlexW2036036824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.